Method and Composition for Treating Seizure Disorders

Abstract

A composition for treating seizure disorders such as epilepsy comprises (i) an anticonvulsant drug of the hydantoin family; (ii) phytocannabinoid cannabidiol (CBD); and (iii) a fat-soluble vitamin.

1 . Method for treating a patient having a seizure disorder, which is effective to reduce seizure intensity and/or seizure frequency, comprising administering daily to the patient at least (i) an anticonvulsant drug of the hydatoin family in an amount of not greater than about 7 mg/kg of the patient's body weight, (ii) cannabidiol (CBD) in an amount sufficient to inhibit degradation of the anticonvulsant drug by a cytochrome P450 enzyme such that bioavailability of the anticonvulsant drug is increased, (iii) a water-soluble vitamin, and (iv) a fat-soluble vitamin. 
     
     
         2 . Method of  claim 1  wherein the anticonvulsant drug is selected from the group consisting of ethotoin, fosphenytoin, mephenytoin and phenytoin. 
     
     
         3 . Method of  claim 1  wherein the CBD is extracted from  Cannabis indica  or  Cannabis sativa  or a hybrid of  Cannabis indica  and  Cannabis sativa.    
     
     
         4 . Method of  claim 1  wherein the CBD is organic CBD. 
     
     
         5 . Method of  claim 1  wherein the CBD is pure or synthetic CBD. 
     
     
         6 . Method of  claim 1  wherein the CBD is obtained from hemp or by extracting hempseed oil. 
     
     
         7 . Method of  claim 1  wherein the CBD is in an amount of from about 0.5 to about 1.0 mg/kg of the patient's body weight. 
     
     
         8 . Method of  claim 1  wherein the water-soluble vitamin is selected from the group consisting of folic acid, folate, vitamin B9 and vitamin B12. 
     
     
         9 . Method of  claim 8  wherein the water-soluble vitamin is folic acid. 
     
     
         10 . Method of  claim 1  wherein the water-soluble vitamin is in an amount of from about 0.5 to about 1.0 mg/kg of the patient's body weight. 
     
     
         11 . Method of  claim 1  wherein the fat-soluble vitamin is selected from the group consisting of vitamins A, D, E and K. 
     
     
         12 . Method of  claim 11  wherein the fat-soluble vitamin is vitamin A. 
     
     
         13 . Method of  claim 1  wherein the fat-soluble vitamin is in an amount of about 100-2000 IU/kg of the patient's body weight. 
     
     
         14 . Method of  claim 1  wherein the anticonvulsant drug is in an amount of not greater than about 2 mg/kg of the patient's body weight. 
     
     
         15 . Method of  claim 1  wherein the seizure disorder is epilepsy. 
     
     
         16 . Method for treating a patient having a seizure disorder, which is effective to reduce seizure intensity and/or seizure frequency, comprising administering daily to the patient at least (i) an anticonvulsant drug of the hydatoin family in an amount of not greater than about 7 mg/kg of the patient's body weight, (ii) cannabidiol (CBD) in an amount sufficient to inhibit degradation of the anticonvulsant drug by a cytochrome P450 enzyme such that bioavailability of the anticonvulsant drug is increased, (iii) a water-soluble vitamin in an amount of from about 0.5 to about 1.0 mg/kg of the patient's body weight, and (iv) a fat-soluble vitamin in an amount of at least about 100-2000 IU/kg of the patient's body weight. 
     
     
         17 . Method of  claim 16  wherein the anticonvulsant drug is in an amount of not greater than about 2 mg/kg of the patient's body weight. 
     
     
         18 . Method of  claim 17  wherein the seizure disorder is epilepsy. 
     
     
         19 . Method for treating a patient having a seizure disorder, which is effective to reduce seizure intensity and/or seizure frequency, comprising
 (a) administering daily to the patient at least (i) an anticonvulsant drug of the hydatoin family in an amount of not greater than about 7 mg/kg of the patient's body weight, (ii) CBD in an amount of from about 0.5 to about 1.0 mg/kg of the patient's body weight, and (iii) a fat-soluble vitamin in an amount of about 100-2000 IU/kg of the patient's body weight;   (b) separately administering to the patient at least a water-soluble vitamin in an amount of about 1-20 mg/day.   
     
     
         20 . Method of  claim 19  wherein the anticonvulsant drug is in an amount of not greater than about 2 mg/kg of the patient's body weight.